276 related articles for article (PubMed ID: 19892863)
21. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.
Avisar I; Weinberger D; Kremer I
Curr Eye Res; 2010 Feb; 35(2):108-15. PubMed ID: 20136420
[TBL] [Abstract][Full Text] [Related]
22. The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency.
Lin CT; Hu FR; Kuo KT; Chen YM; Chu HS; Lin YH; Chen WL
Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6277-85. PubMed ID: 20435600
[TBL] [Abstract][Full Text] [Related]
23. Short-term topical bevacizumab in the treatment of stable corneal neovascularization.
Cheng SF; Dastjerdi MH; Ferrari G; Okanobo A; Bower KS; Ryan DS; Amparo F; Stevenson W; Hamrah P; Nallasamy N; Dana R
Am J Ophthalmol; 2012 Dec; 154(6):940-948.e1. PubMed ID: 22967868
[TBL] [Abstract][Full Text] [Related]
24. Subconjunctival and/or intrastromal bevacizumab injections as preconditioning therapy to promote corneal graft survival.
Fasciani R; Mosca L; Giannico MI; Ambrogio SA; Balestrazzi E
Int Ophthalmol; 2015 Apr; 35(2):221-7. PubMed ID: 24715230
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization.
Ozdemir O; Altintas O; Altintas L; Ozkan B; Akdag C; YĆ¼ksel N
Arq Bras Oftalmol; 2014 Aug; 77(4):209-13. PubMed ID: 25410169
[TBL] [Abstract][Full Text] [Related]
26. Subconjunctival bevacizumab for corneal neovascularization.
Doctor PP; Bhat PV; Foster CS
Cornea; 2008 Oct; 27(9):992-5. PubMed ID: 18812760
[TBL] [Abstract][Full Text] [Related]
27. Effects of subconjunctival tocilizumab versus bevacizumab in treatment of corneal neovascularization in rabbits.
Yoo AR; Chung SK
Cornea; 2014 Oct; 33(10):1088-94. PubMed ID: 25119962
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of sub-conjunctival and topical bevacizumab in high-risk corneal transplant survival.
Bhatti N; Qidwai U; Hussain M; Kazi A
J Pak Med Assoc; 2013 Oct; 63(10):1256-9. PubMed ID: 24392555
[TBL] [Abstract][Full Text] [Related]
29. Early Application of Bevacizumab After Sclerocorneal Grafting for Patients With Severe Late-Stage Ocular Chemical Burns.
Huang ST; Zhou T; Yang YX; Zhou BB; Yin XF; Zhou SY
Cornea; 2020 Jun; 39(6):754-760. PubMed ID: 32040009
[TBL] [Abstract][Full Text] [Related]
30. Ranibizumab injection for corneal neovascularization refractory to bevacizumab treatment.
Ahn YJ; Hwang HB; Chung SK
Korean J Ophthalmol; 2014 Apr; 28(2):177-80. PubMed ID: 24688262
[TBL] [Abstract][Full Text] [Related]
31. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization.
Koenig Y; Bock F; Horn F; Kruse F; Straub K; Cursiefen C
Graefes Arch Clin Exp Ophthalmol; 2009 Oct; 247(10):1375-82. PubMed ID: 19415316
[TBL] [Abstract][Full Text] [Related]
32. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model.
Sener E; Yuksel N; Yildiz DK; Yilmaz B; Ozdemir O; Caglar Y; Degirmenci E
Curr Eye Res; 2011 Nov; 36(11):1005-13. PubMed ID: 21999227
[TBL] [Abstract][Full Text] [Related]
33. Clinico-biochemical correlation of the effect of subconjunctival bevacizumab for corneal neovascularization.
Agarwal S; Angayarkanni N; Iyer G; Srinivasan B; Natarajan R; Charola S; Arumugam S; Padmanabhan P
Cornea; 2014 Oct; 33(10):1016-21. PubMed ID: 25090164
[TBL] [Abstract][Full Text] [Related]
34. Intrastromal delivery of bevacizumab using microneedles to treat corneal neovascularization.
Kim YC; Grossniklaus HE; Edelhauser HF; Prausnitz MR
Invest Ophthalmol Vis Sci; 2014 Sep; 55(11):7376-86. PubMed ID: 25212779
[TBL] [Abstract][Full Text] [Related]
35. Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs.
Koenig Y; Bock F; Kruse FE; Stock K; Cursiefen C
Cornea; 2012 Aug; 31(8):887-92. PubMed ID: 22362005
[TBL] [Abstract][Full Text] [Related]
36. The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas.
Oh JY; Kim MK; Shin MS; Lee HJ; Lee JH; Wee WR
Curr Eye Res; 2009 Feb; 34(2):85-91. PubMed ID: 19219678
[TBL] [Abstract][Full Text] [Related]
37. Effect of locally administered anti-CD154 (CD40 ligand) monoclonal antibody on survival of allogeneic corneal transplants.
Qian Y; Dana MR
Cornea; 2002 Aug; 21(6):592-7. PubMed ID: 12131037
[TBL] [Abstract][Full Text] [Related]
38. Subconjunctival bevacizumab for vascularized rejected corneal grafts.
Awadein A
J Cataract Refract Surg; 2007 Nov; 33(11):1991-3. PubMed ID: 17964413
[TBL] [Abstract][Full Text] [Related]
39. Corneal penetration of topical and subconjunctival bevacizumab.
Dastjerdi MH; Sadrai Z; Saban DR; Zhang Q; Dana R
Invest Ophthalmol Vis Sci; 2011 Nov; 52(12):8718-23. PubMed ID: 22003112
[TBL] [Abstract][Full Text] [Related]
40. Subconjunctival bevacizumab for corneal neovascularization.
Zaki AA; Farid SF
Acta Ophthalmol; 2010 Dec; 88(8):868-71. PubMed ID: 19519730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]